Press Release Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update 2 hours ago
Press Release Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 Aug 11